Tissue Regenix Dermis Trial: Mr Henry Ian Kelly (patient)
Tissue Regenix Dermis Trial: Mrs Alma McDermott (patient)
Tissue Regenix Dermis Trial: Mr George Little (patient)
Increasing life expectancy is driving demand for new healthcare technologies to aid the process of ageing. Whether through cardiac, vascular, wound or orthopaedic treatments, Tissue Regenix is developing a pipeline of products to improve quality of life and agility.
Tissue Regenix is developing products that could help repair the knee. Our dCELL® process allows us to decellularise porcine meniscus, which could then be implanted into the patient’s knee, replacing the original, damaged tissue and potentially acting as a scaffold to accelerate natural repair.
dCELL® human dermis patches may allow a better chance of healing for chronic wounds (including ulcers and burns) and potentially faster healing for acute wounds (including surgical incisions and traumatic injuries).
dCELL® heart valves replace the patient’s own damaged valves, and may provide a biological scaffold for population by patient's own cells.
dCELL® decellularises porcine meniscus for implanting into the patient’s knees as a matrix to attract stem-cells and allow natural healing of damaged joints.
dCELL® vascular patches can be used in vascular surgery to provide effective closure with evidence of integration with patient’s own vessel.
Sign up to our mailing list to keep up with the latest news and developments from Tissue Regenix.
View alerts sign-up page
© Tissue Regenix Group plc 2017
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.